Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares...
22 June 2019 - 6:04AM
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage
biotechnology company focused on discovering and developing novel
small molecule drugs for the treatment of cancer and other
life-threatening diseases, today announced the closing of its
previously announced public offering of 14,375,000 shares of common
stock, including 1,875,000 shares sold pursuant to the
underwriters’ exercise in full of their option to purchase
additional shares. Gross proceeds from the offering at a public
offering price of $4.00 per share, before underwriting discounts
and commissions and offering expenses, were $57.5 million.
SVB Leerink, Wells Fargo Securities and William
Blair acted as joint book-running managers for the offering.
A shelf registration statement relating to the
offered shares of common stock was filed with the Securities and
Exchange Commission (SEC), and was declared effective. A final
prospectus supplement and accompanying prospectus relating to the
offering have been filed with the SEC and are available on the
SEC’s website, located at www.sec.gov. Copies of the
prospectus related to the offering may be obtained from SVB Leerink
LLC, Attention: Syndicate Department, One Federal Street, 37th
Floor, Boston, Massachusetts 02110, by telephone at 800-808-7525,
ext. 6132 or by email at syndicate@svbleerink.com; Wells Fargo
Securities, LLC, Attention: Equity Syndicate Department, 375 Park
Avenue, New York, New York 10152 at 800-326-5897 or email a request
to cmclientsupport@wellsfargo.com; or William Blair & Company,
L.L.C., Attention: Prospectus Department, 150 North Riverside
Plaza, Chicago, IL 60606, or by telephone at 800-621-0687 or email
at prospectus@williamblair.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Investor Relations Contact:
Jennifer
McNealeyir@Calithera.com650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2024 to May 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From May 2023 to May 2024